Inventor · disambiguated record
Gerd Wohlfahrt
Also filed as: WOHLFAHRT GERD
17 granted patents·11 pending applications·67 citations·filing 2001–2024
92Inventor score
Top patents by PatentIndex Score
28 records- 0191US11098032B2Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitorsORION CORP·Filed 2020·Granted Aug 24, 2021·3 cites·11 claims
- 0291US11046713B2Androgen receptor modulating compoundsORION CORP·Filed 2020·Granted Jun 29, 2021·2 cites·2 claims
- 0391US10711013B2Androgen receptor modulating compoundsORION CORP·Filed 2018·Granted Jul 14, 2020·2 cites·17 claims
- 0490US10118933B2Androgen receptor modulating compoundsORION CORP·Filed 2017·Granted Nov 6, 2018·8 cites·3 claims
- 0587US10717726B2Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitorsORION CORP·Filed 2017·Granted Jul 21, 2020·3 cites·35 claims
- 0687US10336697B2Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitorsORION CORP·Filed 2016·Granted Jul 2, 2019·6 cites·30 claims
- 0785US8921378B2Androgen receptor modulating carboxamidesTÖRMÄKANGAS OLLI·Filed 2012·Granted Dec 30, 2014·16 cites·12 claims
- 0881US9657003B2Androgen receptor modulating compoundsORION CORP·Filed 2015·Granted May 23, 2017·3 cites·10 claims
- 0981US2024308989A1Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitorsORION CORP·Filed 2024·Application pending·0 cites
- 1080US8975254B2Androgen receptor modulating compoundsWOHLFAHRT GERD·Filed 2010·Granted Mar 10, 2015·8 cites·8 claims
- 1173US9447091B2Protein kinase inhibitorsORION CORP·Filed 2012·Granted Sep 20, 2016·2 cites·15 claims
- 1273US7390923B2Propionamide derivatives useful as androgen receptor modulatorsORION CORP·Filed 2004·Granted Jun 24, 2008·11 cites·11 claims
- 1370US12030871B2Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitorsORION CORP·Filed 2021·Granted Jul 9, 2024·0 cites·24 claims
- 1468US8809536B22,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseasesORION CORP·Filed 2014·Granted Aug 19, 2014·1 cites·11 claims
- 1567US8492549B22,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous systeme diseasesDIN BELLE DAVID·Filed 2008·Granted Jul 23, 2013·2 cites·34 claims
- 1659US10391082B2Protein kinase inhibitorsORION CORP·Filed 2018·Granted Aug 27, 2019·0 cites·6 claims
- 1759US2025011285A1Cyp11a1 inhibitorsORION CORP·Filed 2022·Application pending·0 cites
- 1855US2024246908A1Tead inhibitorsORION CORP·Filed 2022·Application pending·0 cites
- 1954US2024124431A12,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as cyp11a1 inhibitors for the treatment of prostate cancerORION CORP·Filed 2021·Application pending·0 cites
- 2054US2024174683A1Map4k1 inhibitorsBAYER AG·Filed 2022·Application pending·0 cites
- 2152US8697723B22,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseasesORION CORP·Filed 2013·Granted Apr 15, 2014·0 cites·2 claims
- 2250US2023322724A1Heterocyclic compounds as cbp/ep300 bromodomain inhibitorsAURIGENE ONCOLOGY LTD·Filed 2021·Application pending·0 cites
- 2349US2023192677A1Cyp11a1 inhibitorsORION CORP·Filed 2021·Application pending·0 cites
- 2448US2016346254A1Protein kinase inhibitorsORION CORP·Filed 2016·Application pending·0 cites
- 2544US2011262352A1Aryl piperazine and their use as alpha2c antagonistsDIN BELLE DAVID·Filed 2009·Application pending·0 cites
- 2640US9890139B2CYP17 inhibitors/antiandrogensORION CORP·Filed 2014·Granted Feb 13, 2018·0 cites·22 claims
- 2735US2018312496A1Bicyclic heterocycle derivatives as bromodomain inhibitorsORION CORP·Filed 2016·Application pending·0 cites
- 2823US2004152872A1Method for modifying a protein structureFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gerd Wohlfahrt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →